4D Molecular Therapeutics (4DMT) Stock

4dmoleculartherapeutics.comHealthcare / BioTech & PharmaFounded: 2013Funding to Date: $109MM

4DMT is a biotechnology company focused on pioneering the development of precision gene therapies based on proprietary AAV vectors.

Register To Buy and Sell Shares

For more details on financing and valuation for 4D Molecular Therapeutics (4DMT), register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access 4D Molecular Therapeutics (4DMT)’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like 4D Molecular Therapeutics (4DMT).

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

David Kirn MD
Chief Executive Officer, Chairman & Co-Founder
Melissa Kotterman Ph.D
Vice President, Discovery & Engineering & Co-Founder
August Moretti JD
Chief Financial Officer
Fred Kamal Ph.D
Chief Technology Officer
Peter Francis MD
Chief Medical Officer
Theresa Janke
Co-Founder & Chief Operating Officer
Leisa Johnson
Vice President, Pre-Clinical R&D, Pharmacology & Toxicology Program Leader, Lung Therapeutic Area
David Schaffer Ph.D
Co-Founder, Chief Scientific Advisor & Board Member

Board Members

Charles Theuer MD
Deborah Marshall JD
Sidley Austin
Margi McLaughlin Ph.D
David Schaeffer Ph.D
Hoyoung Huh Ph.D
David Kirn MD
Jacob Chacko MD
Tony Yao Ph.D
ArrowMark Partners

News Highlights

Astellas signs $962m rare eye disease deal with 4D Molecular Therapeutics
Astellas Pharma has signed a $962m deal with 4D Molecular Therapeutics (4DMT) for rights to use one of 4DMT's gene therapy vectors for treating a rare eye disease. The US genetic medicines company will receive $20m upfront for its R100 vector technology and could receive up to $942.5m in future fees and milestones. Astellas will be responsible for research, development, manufacturing, and commercialisation and has an option to add two more disease targets.
4DMT Gains Alignment with FDA on Plan to Lift Clinical Hold on Phase 1/2 INGLAXA Clinical Trial for 4D-310 for Fabry Disease Cardiomyopathy
4D Molecular Therapeutics (4DMT) has achieved alignment with the FDA over a plan to lift a clinical hold on the Phase 1/2 INGLAXA clinical trial involving 4D-310, a treatment for Fabry disease cardiomyopathy. The company has amended the INGLAXA protocol to decrease the risk of atypical hemolytic uremic syndrome (aHUS), and interim clinical data from the trial is expected to be presented in Q1 2024.
Astellas, 4D Molecular Therapeutics Agree to Licensing Deal
Astellas Pharma and 4D Molecular Therapeutics (4DMT) have agreed to a licensing deal that allows Astellas to use 4DMT's intravitreal retinotropic R100 vector. The R100 vector is used for the delivery of genetic payloads in the treatment of retinal diseases. Astellas initially has rights to one genetic target, with the option to include two more for additional fees.
Updated on: May 23, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.